The stock of Assembly Biosciences Inc (ASMB) has gone down by -16.71% for the week, with a 3.70% rise in the past month and a -1.62% drop in the past quarter. The volatility ratio for the week is 13.19%, and the volatility levels for the past 30 days are 8.23% for ASMB. The simple moving average for the past 20 days is -11.61% for ASMB’s stock, with a 13.69% simple moving average for the past 200 days.
Is It Worth Investing in Assembly Biosciences Inc (NASDAQ: ASMB) Right Now?
The stock has a 36-month beta value of 0.65. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ASMB is 4.50M, and at present, short sellers hold a 0.36% of that float. On September 25, 2024, the average trading volume of ASMB was 19.04K shares.
ASMB) stock’s latest price update
Assembly Biosciences Inc (NASDAQ: ASMB)’s stock price has dropped by -6.83 in relation to previous closing price of 16.26. Nevertheless, the company has seen a loss of -16.71% in its stock price over the last five trading days. zacks.com reported 2024-09-16 that Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Analysts’ Opinion of ASMB
Many brokerage firms have already submitted their reports for ASMB stocks, with Jefferies repeating the rating for ASMB by listing it as a “Buy.” The predicted price for ASMB in the upcoming period, according to Jefferies is $35 based on the research report published on September 20, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ASMB reach a price target of $3.50. The rating they have provided for ASMB stocks is “Neutral” according to the report published on September 13th, 2021.
ASMB Trading at -2.25% from the 50-Day Moving Average
After a stumble in the market that brought ASMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.40% of loss for the given period.
Volatility was left at 8.23%, however, over the last 30 days, the volatility rate increased by 13.19%, as shares sank -4.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.43% lower at present.
During the last 5 trading sessions, ASMB fell by -16.71%, which changed the moving average for the period of 200-days by +63.96% in comparison to the 20-day moving average, which settled at $17.11. In addition, Assembly Biosciences Inc saw 53.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ASMB starting from White Nicole S, who sale 785 shares at the price of $14.23 back on Aug 02 ’24. After this action, White Nicole S now owns 12,068 shares of Assembly Biosciences Inc, valued at $11,173 using the latest closing price.
Okazaki Jason A, the CEO and President of Assembly Biosciences Inc, sale 981 shares at $14.23 during a trade that took place back on Aug 02 ’24, which means that Okazaki Jason A is holding 15,101 shares at $13,962 based on the most recent closing price.
Stock Fundamentals for ASMB
Current profitability levels for the company are sitting at:
- -2.35 for the present operating margin
- 0.99 for the gross margin
The net margin for Assembly Biosciences Inc stands at -2.12. The total capital return value is set at -0.68. Equity return is now at value -101.78, with -50.15 for asset returns.
Based on Assembly Biosciences Inc (ASMB), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 13.94.
Currently, EBITDA for the company is -64.2 million with net debt to EBITDA at 0.35. When we switch over and look at the enterprise to sales, we see a ratio of 3.66. The receivables turnover for the company is 53.7for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.74.
Conclusion
To sum up, Assembly Biosciences Inc (ASMB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
